Search

Your search keyword '"Murakami, Marohito"' showing total 46 results
Start Over Author "Murakami, Marohito"
46 results on '"Murakami, Marohito"'

1. Clinical relevance of proteinuria selectivity index and fractional excretion of sodium in patients with nephrotic syndrome

Author

Nakayama, Takashin, Azegami, Tatsuhiko, Yamaguchi, Shintaro, Hirano, Keita, Komatsu, Motoaki, Fujii, Kentaro, Futatsugi, Koji, Urai, Hidenori, Kawaguchi, Takahisa, Itoh, Tomoaki, Yoshimoto, Norifumi, Hagiwara, Aika, Hishikawa, Akihito, Matsuda, Hiroto, Ando, Takashi, Yamaji, Yasuyoshi, Murakami, Marohito, Hashiguchi, Akinori, Kaneko, Yuko, Yokoo, Takashi, and Hayashi, Kaori

Published
2024
Full Text
View/download PDF

4. Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in low-renin hypertension

Author

Naitoh, Mareo, Suzuki, Hiromichi, Arakawa, Kouki, Matsumoto, Akira, Ichihara, Atsuhiro, Matsuda, Hiroto, Kubota, Eiji, Murakami, Marohito, Nakamoto, Hidetomo, and Saruta, Takao

Subjects
ACE inhibitors -- Physiological aspects, Captopril -- Physiological aspects, Renin-angiotensin system -- Physiological aspects, Hypertension -- Physiological aspects, Bradykinin -- Physiological aspects, Dogs as laboratory animals -- Physiological aspects, Biological sciences
Abstract

The effects of angiotensin-converting enzyme (ACE) inhibitors such as captopril and imidaprilat during low-renin hypertension were analyzed in conscious deoxycorticosterone acetate (DOCA) salt hypertensive dogs. Administration of captopril and imidaprilat on conscious DOCA salt hypertensive dogs increased urine flow rate and reduced mean arterial pressure. The significant hypotensive and renal effects of the ACE inhibitors were due to the action of bradykinin and prostaglandin formation which was mediated by angiotensin II synthesis in the kidney.

Published
1997

5. Effect of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs

Author

Naitoh, Mareo, Suzuki, Hiromichi, Murakami, Marohito, Matsumoto, Akira, Arakawa, Kouki, Ichihara, Atsuhiro, Nakamoto, Hidetomo, Oka, Kiyoshi, Yamamura, Yoshitaka, and Saruta, Takao

Subjects
Arginine -- Physiological aspects, Vasopressin -- Physiological aspects, Diuresis -- Analysis, Biological sciences
Abstract

Oral administration of selective arginine vasopressin AVP V1 receptor antagonist OPC-21268 causes an increase in cardiac output and renal function while that of AVP V2 receptor antagonist OPC-31260 results in an increase in plasma renin activity, plasma levels and serum sodium concentration of AVP in dogs with congestive heart failure. AVP V1 receptor antagonist does not affect serum electrolytes and hormones while AVP V2 receptor antagonist induces water diuresis. Combined administration of both the receptor antagonists triggers additive metabolic and renal responses and supra-additive hemodynamic responses.

Published
1994

18. Survey of novel influenza A (H1N1) infection and vaccination in dialysis facilities in the Tokyo Tama area

Author

Ando, Ryoichi, primary, Kaname, Shinnya, additional, Yoshida, Masaharu, additional, Murakami, Akira, additional, Kurimoto, Yoshinao, additional, Higaki, Masao, additional, Ozawa, Sho, additional, Matsukawa, Shigeaki, additional, Miyakawa, Hiroshi, additional, Murakami, Marohito, additional, Koizumi, Hiroshi, additional, Sugizaki, Hiroaki, additional, Yamada, Akira, additional, and Nagasawa, Toshihiko, additional

Published
2010
Full Text
View/download PDF

19. The Short Treatment with the Angiotensin Receptor Blocker Candesartan Surveyed by Telemedicine (STAR CAST) Study: Rationale and Study Design

Author

Sasamura, Hiroyuki, primary, Nakaya, Hideaki, additional, Julius, Stevo, additional, Takebayashi, Toru, additional, Sato, Yuji, additional, Uno, Hajime, additional, Takeuchi, Masahiro, additional, Ishiguro, Kimiko, additional, Murakami, Marohito, additional, Ryuzaki, Munekazu, additional, and Itoh, Hiroshi, additional

Published
2008
Full Text
View/download PDF

28. Modulation of Angiotensin II Type 1 Receptor mRNA Expression in Human Blood Cells: Comparison of Platelets and Mononuclear Leucocytes.

Author

SUZUKI, HIROMICHI, primary, SHIBATA, HIROTAKA, additional, MURAKAMI, MAROHITO, additional, SATO, ATSUHISA, additional, NAITO, MAREO, additional, ICHIHARA, ATSUHIRO, additional, MATSUMOTO, AKIRA, additional, TSUJIMOTO, GOZOH, additional, HIRASAWA, AKIRA, additional, HORIE, KUNIKO, additional, and SARUTA, TAKAO, additional

Published
1995
Full Text
View/download PDF

30. Feasibility of Regression of Hypertension Using Contemporary Antihypertensive Agents.

Author

Sasamura, Hiroyuki, Nakaya, Hideaki, Julius, Stevo, Tomotsugu, Naoki, Sato, Yuji, Takahashi, Fumiaki, Takeuchi, Masahiro, Murakami, Marohito, Ryuzaki, Munekazu, and Itoh, Hiroshi

Subjects
ANGIOTENSINS, HYPERTENSION, ANTIHYPERTENSIVE agents, CANDESARTAN, KAPLAN-Meier estimator
Abstract

BACKGROUND Recently, we reported that transient treatment of genetically hypertensive rats with high-dose angiotensin receptor blocker (ARB) causes regression of established hypertension. In this study, we investigated whether treatment with candesartan or nifedipine controlled-release (CR) resulted in a sustained regression of hypertension in humans. METHODS Patients aged 30 to 59 years with untreated stage 1 essential hypertension and a family history of hypertension were treated with the antihypertensive agents candesartan (n = 124) or nifedipine CR (n = 120). After 1 year of treatment (phase 1), the medications were tapered and discontinued (phase 2). During phase 2, home and office blood pressures were monitored for another year to assess posttreatment reoccurrence of stage 1 hypertension. RESULTS In phase 1, after 1 year of treatment a similarly substantial BP decrease was seen in the candesartan (−24.5/16.1mm Hg) and nifedipine (−26.8/18.0mm Hg) groups. In phase 2 there was a substantial reoccurrence of hypertension; at the study end, only 1 patient was able to continue without antihypertensive medication. However, a Kaplan-Meier analysis revealed a significant delay of reoccurrence of hyper tension (P = 0.0001) in the candesartan group. CONCLUSIONS One year of treatment with candesartan or nifedipine CR was not associated with marked regression of hypertension in humans at the standard doses used in this trial. However, withdrawal of candesartan was associated with a slightly longer delay before restarting medications. Further studies with larger doses of candesartan given over a longer time are required to determine whether such a regimen may induce sustainable and clinically relevant reversal of hypertension and alteration in its natural history. [ABSTRACT FROM PUBLISHER]

Published
2013

43. Effects of Endothelin on Systemic and Renal Haemodynamics and Neuroendocrine Hormones in Conscious Dogs

Author

Nakamoto, Hidetomo, Suzuki, Hiromichi, Murakami, Marohito, Kageyama, Yo, Ohishi, Akira, Fukuda, Keiichi, Hori, Shingo, and Saruta, Takao

Abstract

1. The effects of endothelin on systemic and renal haemodynamics and plasma concentrations of neuroendocrine hormones including plasma renin activity, aldosterone, adrenocorticotropic hormone, Cortisol, catecholamines and arginine vasopressin were investigated in 18 conscious dogs. 2. Bolus injection of 4 pmol of endothelin/kg did not cause any significant changes in haemodynamics. Mean arterial pressure was elevated by both doses of 40 pmol/kg [91 ± 2 to 99 ± 2 mmHg (12.1 ± 0.3 to 13.2 ± 0.3 kPa), P < 0.05] or 200 pmol/kg [93 ± 2 to 107 ± 3 mmHg (12.4 ± 0.3 to 14.3± 0.4 kPa), P < 0.01], the latter dose increasing cardiac output (14%, P < 0.05) and heart rate (9%, P < 0.05), and the former reducing these parameters (14% and 8%, P < 0.05, respectively). 3. In contrast with the various changes in systemic haemodynamics, renal blood flow transiently increased immediately after bolus injection in a dose-dependent manner (28%, P < 0.05, 50%, P < 0.01 and 110%, P < 0.01 with 4, 40 and 200 pmol of endothelin/kg, respectively). This transient elevation of renal blood flow was followed by a gradual decrease (16%, P < 0.05; 31%, P < 0.01 and 36%, P < 0.01) at 10 min. 4. All neurohormones were elevated in a dose-dependent manner. 5. Among these hormones, arginine vasopressin and plasma renin activity reached a peak level at 5 min (from 2.21 ± 0.45 to 6.37 ± 0.60 pmol/l, P < 0.01, and from 0.65 ± 0.08 to 1.09 ± 0.10 pmol of angiotensin 1 h−1 ml−1P < 0.01, respectively) after bolus injection of 200 pmol of endothelin/kg, whereas adrenocorticotropic hormone and Cortisol reached a peak level at 15 min (from 6.0 ± 0.7 to 18.2 ± 1.5 pmol/l, P < 0.01, and from 4.4 ± 0.9 to 16.5 ± 2.7 × 10−2 μmol/l, P < 0.01, respectively). 6. These results suggest that endothelin is a potent vasoconstrictive peptide in vivo with a marked effect on the renal vascular system, and that it induces elevation of vasoactive hormones directly and/or through central effects.

Published
1989
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results